BIA
CNTA

Bell Investment Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Bell Investment Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31
Closed -$446 – 1901
2025
Q1 		$446 Hold
31
– – ﹤0.01% 1798
2024
Q4 		$520 Buy
+31
New +$514 ﹤0.01% 1755

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bell Investment Advisors's CNTA Position: Q2 2025 in Review

Bell Investment Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2025, closing a stake of 31 shares — an estimated $446 sold.

Bell Investment Advisors first reported a position in CNTA in Q4 2024 and held it in 2 quarters. The position peaked at $520 in Q4 2024. 117 funds tracked by Wall St. Rank hold CNTA as of Q2 2025.

  • Bell Investment Advisors reported no remaining Centessa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Bell Investment Advisors sold 31 Centessa Pharmaceuticals shares in Q2 2025, an estimated $446.
  • Bell Investment Advisors first reported a position in Centessa Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Bell Investment Advisors's Centessa Pharmaceuticals position peaked at $520 in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2025.

Based on Bell Investment Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.